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This review will utilize essential questions about nontuberculous mycobacterial (NTM) lung dis-
ease to succinctly address important new developments in the pathogenesis, diagnosis and
management of NTM lung disease with a focus on practical information and “bottom line” an-
swers.
1) What do I tell my patients who ask, “where did I get this infection” and, “should I take
showers”?
2) What is the connection between bronchiectasis and the acquisition of NTM lung
infection?
3) What other factors are important in the pathogenesis of NTM lung disease?
4) Why does it seem that am I seeing more new NTM lung disease patients?
5) Why is the diagnosis of NTM lung disease so complicated and does the diagnosis of NTM
lung infection obligate specific treatment?
6) Unlike traditional tuberculosis, what is behind the irrelevance of most in vitro sus-
ceptibility testing reports for NTM infections?
7) Is there anything new for the management of patients with Mycobacterium avium
complex lung disease? How does the radiographic appearance influence treatment?E.B. Moncrief Distinguished Professorship.
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418 T.R. Aksamit et al.8) Is there anything new for the management of patients with Mycobacterium abscessus
lung disease?
9) What about the management of other NTM respiratory pathogens?
10) Is there a role for the use of macrolide monotherapy for non-cystic fibrosis bronchi-
ectasis?
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The NTM are a widely diverse group of organisms with a
broad spectrum of virulence and potential for causing dis-
ease in humans [1]. A plethora of newly identified NTM
species reflects the progress in genomic sequencing tech-
niques applied to the differentiation of mycobacterial spe-
cies. Clinicians are faced with a steady stream of new NTM
species names and the accompanying responsibility for
determining the clinical impact of those new species. There
is also an increasing awareness that NTM lung diseases are
becoming more prevalent. The following discussion will
utilize the top ten essential questions about NTM lung dis-
ease as a platform to succinctly discuss important new de-
velopments in the pathogenesis, diagnosis and management
of NTM lung disease with a focus on practical information,
the concerns of clinicians, and “bottom line” answers.
1) What do I tell my patients who ask, “where did I get
this infection” and, “should I take showers”?
The source of NTM that cause lung disease is still assumed
to be the environment, with increasing concern that biofilms
that form in municipal water sources may be a significant
source for NTM. Feazel et al. analyzed rRNA gene sequences
from 45 showerhead sites around the U.S [2]. Sequences
indicative of Mycobacterium avium were identified in 20% of
showerhead swabs. A quantitative PCRwithM. avium specific
primers was also used to screen DNAs from 32 biofilm and 14
water sources and M. avium DNA was detected in 20 addi-
tional biofilm swab samples in which M. avium had not been
encountered utilizing the RNA gene libraries [2].
Using microbiologic techniques Nishiuchi et al. reported
the recovery of M. avium complex (MAC) from residential
bathrooms of patients with pulmonary MAC disease [3]. M.
avium complex was isolated from 10/371 patient residence
cultures versus 1/333 control households. Two patients with
MAC lung disease were found to have identical sputum and
bathroom MAC genotypes. Falkinham also isolated NTM
from the household water systems of 59% of NTM patients
sampled [4]. In 7 households, the patient isolate and 1
plumbing isolate exhibited similar genotype patterns. Twoadditional reports have demonstrated identical genotypes
of MAC isolated from plumbing and MAC isolates obtained
from humans with MAC lung disease, including one with
conventional MAC lung infection and one with
hypersensitivity-like lung disease [5,6]. These provocative
data support the contention that at least some patients
acquire NTM pathogens including M. avium from household
plumbing. It is still unknown, however, how much of a risk
NTM in municipal water and household plumbing present
and whether these water sources are a significant or com-
mon source of NTM for the majority of patients with NTM
lung disease [7,8]. It is also not certain that avoidance of
showers without avoidance of other potential aerosol
generating activities associated with running water in the
home would eliminate the risk of household NTM trans-
mission [8]. Interventions such as increasing the tempera-
ture of the hot water heater to 130 Fahrenheit or
changing shower heads at regular intervals might decrease
risk of NTM transmission but the impact of these steps is not
known [4]. Moreover, limited experience suggests that
cleaning shower heads with bleach may not result in sus-
tained decreased exposure risk to NTM over time so that no
clear recommendations can be made regarding the efficacy
or optimal timing of regular cleaning of shower heads with
bleach. It is also still unknown whether exposure to specific
soil-based sources of NTM organisms may contribute to the
development of NTM lung disease. It is important to
emphasize, however, that nosocomial NTM disease has
been linked to municipal water (tap-water) exposure [1].
Bottom Line: In our opinion it is too early to make
broad conclusions or recommendations about the risk of
showering, or other municipal water exposure, in pa-
tients with NTM lung disease and underlying diseases
such as bronchiectasis. Concerned patients could
consider raising hot water heater temperatures, treating
shower heads with bleach monthly or even changing
shower heads at regular intervals although the effec-
tiveness of these interventions for preventing NTM lung
disease is unknown.
2) What is the connection between bronchiectasis and
the acquisition of NTM lung infection?
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tricably linked. Twenty per cent of cystic fibrosis patients
and 10% of primary ciliary dyskinesia patients have NTM
recovered from respiratory specimens, which strongly
suggests, at least for some patients, a predisposing alter-
ation in airway-surface defenses [1]. Kim et al. from the
National Institutes of Health (NIH) reported a study of 63
patients (95% female) with a characteristic body habitus
and NTM lung disease [8]. In this referral population, the
BMI was significantly lower and the height significantly
greater than matched controls. This population also had
higher rates of scoliosis (51%), pectus excavatum (11%), and
mitral valve prolapse (9%). There were no recognized im-
mune defects such as cell-mediated dysfunction or
cytokine-pathway abnormalities identified in these pa-
tients. In another similar recent report investigators from
National Jewish Health (NJH) again noted the character-
istic body habitus of female MAC lung disease patients but
found, in contrast to the NIH study, decreased cytokine
(interferon-gamma and IL-10) response of stimulated pe-
ripheral blood monocytes from MAC patients compared
with controls [9]. The NIH study also noted a higher inci-
dence of cystic fibrosis transmembrane conductance regu-
lator (CFTR) gene mutations (36%) compared with a
matched control population. There was no consistent cor-
relation between sweat chloride concentrations and CFTR
variants. It has recently been noted in Japan that patients
presenting with pulmonary NTM disease have mutations in
the CFTR gene significantly more frequently than in the
general population [10]. In a recent study, patients het-
erozygous for CFTR mutations were found to have abnormal
nasal potential differences compared to controls suggest-
ing a subtle mucosal ion transport abnormality and possible
mechanism for developing bronchiectasis [11]. To date,
however, there are no clear mechanistic connections be-
tween single CFTR mutations, the characteristic body
habitus described above and the pathogenesis of
bronchiectasis.
In some patients with NTM lung disease, primarily
nonsmoking adult women, nodular infiltrates often pre-
cedes the development of cylindrical bronchiectasis
which is in contrast to cystic fibrosis patients in whom
NTM lung disease develops distinctly and consistently
after bronchiectasis is long established. It is likely that
the answer to the “chicken or egg” question of whether
bronchiectasis or NTM infection comes first is “yes”. That
is to say there may be many phenotypic pathways to the
development of bronchiectasis with or without NTM lung
disease.
Bottom Line: Pre-existing bronchiectasis is an
important predisposition for acquiring NTM respiratory
infection. Female patients with a specific morphotype
appear to be predisposed to the development of bron-
chiectasis with or without NTM lung diseases although
the exact pathophysiologic mechanisms are still being
investigated. Patients with known bronchiectasis for
any reason should be screened for NTM infection
and should be considered for evaluation of genetic or
hereditary causes of bronchiectasis. The natural history
of the development of NTM lung disease and/or bron-
chiectasis remains incompletely understood at this
time.3) What other factors are important in the pathogenesis
of NTM lung disease?As with Mycobacterium tuberculosis, tumor-necrosis
factor alpha (TNF-a) blockers are a potent predisposition
for NTM infections. Winthrop et al. recently published data
from the United States Food and Drug Administration (FDA)
MedWatch database for reports of NTM disease in patients
receiving TNF-a blocker therapy [12]. NTM infections were
associated with all available TNF-a blockers and MAC was
the NTM species most commonly implicated. Extrapulmo-
nary disease was common (44%) and 9% of patients had
died at the time their infection was reported. TNF-a
blockers are unquestionably an important predisposing
factor for potentially serious, even fatal, NTM infection
and must be used with extreme caution in patients with
NTM disease.
The extent to which other immunosuppressive regimens
and biologic agents increase risk is less well defined
although some increased risk is clearly present. Prototypi-
cally, disseminated NTM disease is common in those with
advanced HIV infection or congenital IL-12 or interferon
gamma defects [1]. Conversely, there appears to be little
risk associated with older, “non-biologic” immune sup-
pressive agents used for rheumatoid arthritis such as azo-
thiaprine and methotrexate [12].
Bottom Line: Patients who receive TNF-a blockers
must be evaluated for NTM disease as well as tuberculosis
with initiation of appropriate treatment for the NTM in-
fections to avoid severe or even fatal NTM disease.
Appropriate diagnostic and therapeutic considerations
should also be proportionately applied to those receiving
other biologic agents or immunosuppressive regimens in
the presence of known or suspected NTM disease.
4) Why does it seem that I am seeing more new NTM lung
disease patients?Available data supports the contention that NTM dis-
ease prevalence is increasing. Determining the incidence
and prevalence of NTM lung disease remains difficult
because disease reporting is not mandatory in the U.S.,
and there must be an assessment of the clinical signifi-
cance of individual NTM isolates, as opposed to M. tuber-
culosis, where each isolate is assumed to be associated
with true disease.
In an insightful analysis, Iseman and Marras suggested
that while the incidence of NTM lung disease may be
comparable to tuberculosis, the true prevalence of NTM
lung disease is almost certainly higher than tuberculosis
due to the difficulty in curing patients with NTM lung dis-
ease, versus the relatively high cure rates for tuberculosis
patients, and the subsequent accumulation of NTM patients
who have indolent but essentially incurable disease [13].
The prevalence of NTM lung disease exceeds incidence
given the chronic nature of NTM lung disease.
In a report of four regional healthcare systems based
primarily on NTM laboratory isolation prevalence, the
mean annual NTM disease prevalence was estimated to
be 5.5/100,000, ranging from 1.7/100,000 in Southern
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study suggested an annual increase in prevalence of 2.6%
over the study period. MAC was the most common species
identified in pulmonary cases (4.7cases/100,000 popula-
tion). In perhaps the best and most rigorous NTM preva-
lence study to date, Winthrop et al. took the next
important but more difficult step of matching NTM iso-
lates with the clinical history and radiographic findings of
individuals from whom the NTM isolates had been ob-
tained. In this analysis the prevalence of NTM lung disease
was found to be 8.6/100,000 overall and 20.4/100,000 in
those 50 years of age or older over the 2005e2006 study
period [15].
Bottom Line: NTM lung disease is currently more
common in the U.S. than tuberculosis and appears to be
increasing in prevalence. For post menopausal women,
NTM lung disease associated with bronchiectasis may be a
common and often unrecognized explanation for chronic
cough.
5) Why is the diagnosis of NTM lung disease so compli-
cated and does the diagnosis of NTM lung infection
obligate specific treatment?The NTM share an important characteristic: they are all
found in the environment so that isolation of any NTM
species can be the consequence of environmental
contamination, especially contamination by nonsterile
(tap) water sources including shower heads as well as other
household water, municipal water and environmental
sources. Hence, diagnostic criteria for respiratory NTM
isolates remain necessary to help determine which NTM
isolates are clinically significant [1]. Overall, this decision
must be based on the potential virulence of the NTM iso-
lated, the host from which the organism was isolated and
the source of the clinical specimen from which the NTM was
isolated [16]. Clinicians must remain knowledgeable about
the disease causing potential of at least the most commonly
isolated NTM species.
There areNTM species such asMycobacteriumkansasii and
Mycobacterium szulgai that are almost always associated
with significant disease when isolated from respiratory spec-
imens [1,16]. In some cases, lung disease might be diagnosed
on the basis of one positive culture for these organisms
(especially M. kansasii) [1]. Conversely, there are also NTM
such asMycobacterium simiae andMycobacterium fortuitum
that are usually not respiratory pathogens, even if the NTM
diagnostic criteria are met [17,18]. Lastly, there are NTM
species such asMycobacterium gordonae andMycobacterium
terrae complex that almost always represent contamination
of respiratory specimens [1]. Substantial geographic differ-
ences are present in the distribution of themost commonNTM
lung disease pathogens intra-continentally as well as inter-
continentally. The approach to NTM lung disease warrants
consideration of these differences and underscores the
importance ofmicrobiologic confirmation of specific NTM lung
disease prior to instituting treatment.
The clinician evaluating these patients frequently has to
take into account a number of factors not explicitly
addressed in the NTM diagnostic criteria [1]. One frequently
encountered scenario is the isolation of an NTM species froma patient undergoing therapy for tuberculosis. Jun et al. re-
ported 958 patients with tuberculosis, of whom 68 (7.1%) had
NTM also isolated during tuberculosis therapy [19]. Most pa-
tients (71%) had only one positive NTM culture and only two
patients (3%), both with Mycobacterium abscessus isolates,
were felt to have progressiveNTMdisease after completion of
tuberculosis therapy. The authors concluded that isolation of
NTM in patients with tuberculosis was not uncommon but was
rarely due to invasive or progressiveNTMdisease. Completion
of TB treatment generally trumps consideration of treatment
of concomitant NTM lung disease when present. Neverthe-
less, these patients required follow-up after completion of
tuberculosis therapy, especially with isolation of potentially
virulent NTM species.
In other instances more than one NTM species is present
either synchronously or metachronously. This raises even
more complex questions about appropriate treatment reg-
imens in these circumstances. No expert consensus or
actual data exists to direct the unfortunate clinician
dealing with more than one NTM organism. In some in-
stances combination regimens may need to be considered
but for now, those circumstances must be evaluated on an
individual basis.
Newer diagnostic techniques to augment the current
diagnostic criteria are clearly needed and some are under
investigation. One novel approach to possibly assist in
establishing a diagnosis of NTM lung disease is a serologic
test based on an enzyme immunoassay kit (EIA) detecting
serum IgA antibody to glycopeptidolipid core antigen spe-
cific for MAC [20]. To date the role of this test is not suf-
ficiently sensitive or specific in the diagnosis of MAC lung
disease to be incorporated into current clinical practice.
Even in the setting of an established diagnosis of NTM
lung disease treatment may not always be needed. The
natural history of NTM lung disease remains elusive
including the specific factors that may be associated with
disease progression. Likewise, treatment of NTM lung dis-
ease involves prolonged multidrug regimens with substan-
tial potential side effects and costs. The NTM lung disease
patient and physician must be a priori in clear agreement
that the risks and benefits of NTM lung disease favors
treatment taking into account patient preferences and
expectations. If a component of the decision to proceed
with treatment for NTM lung disease is based on improving
symptoms the clinician should be clear to discern that these
symptoms (e.g. cough) are not attributable to the presence
of frequently concomitant diagnoses of bronchiectasis,
sinus disease, and/or gastroesophageal reflux disease.
If a diagnosis of NTM lung disease is present and treat-
ment not started patients must be followed longitudinally
so as to assess for progressive symptomatic and/or radio-
graphic lung disease warranting reassessment of the risks
and benefits of treatment.
Bottom Line: The diagnosis of NTM lung disease de-
pends on meeting established diagnostic criteria howev-
er, the decision about whether to treat a patient who
meets those criteria still requires considerable clinical
judgment. For most patients with typically indolent NTM
lung disease there is adequate time to carefully consider
the clinical significance of respiratory NTM isolates and
weigh the pros and cons of prolonged and potentially
toxic therapy.
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irrelevance of most in vitro susceptibility testing re-
ports for NTM infections?Perhaps the most frustrating problem in the manage-
ment of patients with NTM diseases is the observation that
in vitro susceptibility testing may not be a guide for
effective in-vivo response to antibiotics, as it is in the
therapy of tuberculosis [1]. The most clinically important
example of this phenomenon is MAC, where there is, so far,
only evidence to support a correlation between in vitro
macrolide susceptibility and in vivo clinical response which
has been confirmed in multiple studies [1]. Both the Clinical
and Laboratory Standard Institute (CLSI) and the American
Thoracic Society (ATS) recommend that new MAC isolates
should be tested in vitro only for susceptibility to macro-
lides [1,21]. Understandably, clinicians still cling to in vitro
susceptibility reports for MAC isolates that list multiple
agents as either ‘susceptible’ or ‘resistant’ based on
in vitro MICs, even though those MICs have not been shown
to correlate with in vivo response to the antibiotics tested.
One of several examples of this phenomenon was reported
from Japan by Kobashi et al. in a recent study showing a
lack of correlation between in vitro susceptibility for MAC
and in vivo response to rifampin, ethambutol and strepto-
mycin [22e25].
Not surprisingly, there are multiple other NTM species
and pathogens that share this frustrating property with MAC
(including Mycobacterium xenopi, M. malmoense, M. sim-
iae, etc.) and while the explanation(s) are not yet forth-
coming, recent work with rapidly growing mycobacteria
(RGM) may offer a window into the complex relationship
between in vitro responses and in vivo effect of antibiotics
for NTM. Macrolide antimicrobial agents act by binding to
the 50S ribosomal subunit and inhibiting peptide synthesis.
Erythromycin methylase (erm) genes, a diverse collection
of methylases that impair binding of macrolides to ribo-
somes, reduce the inhibitory activity of these agents. The
primary mechanism of acquired clinically significant mac-
rolide resistance for some mycobacteria, especially RGM, is
the presence of an inducible erm gene (erm 41) [26,27]. All
isolates of M. abscessus ssp abscessus, M. fortuitum and
several other RGM, but not Mycobacterium chelonae,
contain an inducible erm gene. Parenthetically, there is
also a novel erm gene in M. tuberculosis, which explains the
poor response of M. tuberculosis to macrolide antibiotics.
The most interesting aspect of this inducible gene is that if
an M. fortuitum or M. abscessus ssp abscessus isolate is
exposed to macrolide, the erm gene activity is induced with
subsequent in vivo macrolide resistance which may not be
reflected by the initial in vitro MIC of the organism for the
macrolide! In other words, the organism may appear to be
susceptible in vitro to the macrolide but will not respond to
the macrolide in vivo. It appears to be one mechanism for
the discrepancy between in-vitro susceptibility results and
in vivo responses for M. abscessus ssp abscessus and M.
fortuitum.
This in vivo macrolide resistance that does not affect the
initial in vitro MIC for macrolide has been termed ‘cryptic
resistance’, and requires incubation of an NTM isolate with
macrolide prior to determining an MIC for the macrolide.Increasing numbers of mycobacteriology laboratories are
now incubating RGM clinical isolates with macrolide prior to
testing macrolide “susceptibility” and reporting final mac-
rolide susceptibility.
While there is no erm gene in MAC, could there be other
similar inducible genes that confer in vivo resistance to
other antibiotics for MAC? It is an intriguing, if unproven,
possibility. Van Ingen et al. have recently published a
concise review of the multiple factors that are likely con-
tributors to the paradox of poor correlation between
in vitro antibiotic susceptibility and in vivo response to the
same antibiotics [28].
Bottom Line: Macrolide susceptibility is currently the
only drug category relevant to clinical outcomes in MAC
lung infections. In contrast, treating clinicians must be
aware that the inducible erm gene carried by some
RGM invalidates macrolide susceptibility results certain
species.
7) Is there anything new for the management of patients
with M. avium complex lung disease? How does the
radiographic appearance influence treatment?MAC lung disease is associated radiographically with
upper lobe fibrocavitary densities, which occurs primarily in
men with underlying obstructive lung disease or nodules
and bronchiectasis which occurs primarily in women
without other underlying pulmonary disease. These latter
patients are associated with a specific morphotype,
including low BMI, tall stature, scoliosis, pectus excavatum
and mitral valve prolapse as previously discussed. Most
clinicians rely heavily on CT scan appearances in order to
assess disease type and severity and to determine the
choice of treatment regimens. Most experts agree that the
pathophysiology and clinical behavior of the two groups
should be viewed separately. Ito et al. described predictors
of 5-year mortality in patients with MAC lung disease [29].
After adjusting for multiple cofounders, the presence of
cavitary disease was associated with a higher mortality thus
emphasizing that “patients with cavitary lesions require
immediate treatment for sputum culture conversion and to
improve their chances of survival.” The decision to treat
patients with the nodular/bronchiectatic form of MAC lung
disease, should be based on potential risks and benefits of
therapy for individual patients as noted previously.
Treatment for MAC lung disease is long, expensive, and
frequently associated with drug-related toxicities. Clinical
improvement and 12 months of sputum culture negativity
while on therapy are the goals, although this is frequently
not achievable. Treatment regimens for MAC should consist
of a rifamycin (rifampicin or rifabutin), ethambutol and a
macrolide (azithromycin or clarithromycin) [1]. Therapy
can be given daily or intermittently, depending on the
disease type and severity. Nodular bronchiectasis patterns
by radiography can usually safely be treated by intermit-
tent or three times weekly therapy [30]. Fewer side effects
and cost make intermittent therapy a more palatable op-
tion for many patients. Intermittent therapy has been
shown to be less effective for individuals with cavitary MAC
lung disease, especially if they are accompanied by a his-
tory of COPD, bronchiectasis or previous treatment for MAC
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severe nodular/bronchiectatic disease or disease of either
type unresponsive to initial therapy currently involves daily
three drug therapy as outlined above in addition to IM
streptomycin or IM/IV amikacin usually given TIW [1]. The
optimal duration for parenteral therapy is unknown and
may require 6 months or longer of the agent. The initial use
of parenteral agents has been shown to increase culture
conversion rates, but not improve long-term outcome [32].
Barriers to initiating therapy for cavitary disease include
difficulty obtaining and monitoring drug levels, side effect
profiles of aminoglycosides and patient desires. There is no
evidence to support the use of fluoroquinolones as first line
agents for treating MAC lung disease. The use of macrolide
and fluoroquinolone may be associated with cardiac
toxicity and puts the patient at risk for development of
macrolide resistant MAC disease [33]. Limited data suggests
that for patients who do not tolerate rifamycins, clofazi-
mine may provide an effective alternative, combined with
ethambutol and a macrolide [34]. Adjunctive surgery for
selected patients is associated with favorable treatment
outcomes although experienced mycobacterial lung disease
surgeons remain an important factor for successful out-
comes [35,36].
The role for the inclusion of inhaled amikacin in a
treatment regimen for advance or recalcitrant NTM lung
disease remains uncertain with little available published
data [37]. An ongoing multicenter clinical trial investigating
the addition of inhaled liposomal amikacin for recalcitrant
MAC and M. abscessus lung disease to a stable regimen
promises to shed important light onto this unanswered
question.
An additional critical element in the management of pa-
tients with MAC lung disease is prevention of the emergence
of macrolide resistance. While the role of in vitro suscepti-
bility for other agents remains controversial, it is clear that
the development of macrolide resistance in a MAC isolate
(MIC > 16 mg/ml) is strongly associated with treatment fail-
ure and increased mortality [33]. The most important risk
factors for developing macrolide resistant MAC are macro-
lide monotherapy and the combination of macrolide and
fluoroquinolone without a third companion drug [33].
Recent data has shown that currently recommended
macrolide-based treatment regimens for MAC are associ-
ated with important pharmacologic interactions with
resulting low plasma concentrations of essentially all drugs
including macrolides [38]. Targeted pharmacodynamic
indices for essentially all drugs commonly used in MAC
treatment regimens are seldom met. These findings may at
least partly explain the poor outcomes of the currently
recommended MAC treatment regimens. It is noteworthy
that improvement in these pharmacodynamic parameters
would almost certainly entail increased dosages of the MAC
medications which would be a formidable obstacle to
overcome for many patients with MAC lung disease [39].
The timing of when to repeat imaging after the initiation
of treatment can be confusing with no established guide-
lines available as the clinical disease course can vary from
one individual to another. While the desired response is
sputum conversion and imaging improvement, the radio-
graphic evolution, especially with nodular bronchiectasis, is
unclear and often unrewarding. With increasing evidence tosuggest that the cumulative radiation dose is associated
with increased risk of cancer, the need to limit unnecessary
radiographic studies is pertinent to the field of NTM lung
disease [40].
Bottom Line: The management of MAC lung disease is
dependent on in vitro susceptibility of MAC isolates for
macrolides and the inclusion of macrolides in the treat-
ment regimen with companion medications adequate to
prevent the emergence of macrolide resistance. Surgery
for highly selected patients by experienced thoracic
surgeons can also improve MAC treatment outcomes.
Cavitary MAC lung disease is associated with a higher
mortality and should prompt initiation of aggressive
therapy which would likely include an aminoglycoside
and consideration of surgical intervention.
8) Is there anything new for the management of patients
with M. abscessus lung disease?
Overall, the treatment of M. abscessus lung disease re-
mains difficult with inconsistent results. Jeon et al.
recently reported the results of therapy for a series of 69
patients (84% female, mean age 56 years) with M. abscessus
lung disease [41]. These authors treated the patients with a
regimen consisting of an initial 1 month of parenteral
therapy with amikacin 15 mg/kg/day and cefoxitin 200 mg/
kg/day while hospitalized, in combination with oral medi-
cations including clarithromycin 1000 mg/day, ciprofloxacin
1000 mg/day, and doxycycline 200 mg/day for more than 12
months (median 24 months). Forty-seven of 69 patients
(68%) converted sputum to negative with a median time of 1
month. Sputum conversion with macrolide resistant strains
occurred in 27% of patients vs. 71% with macrolide sus-
ceptible strains. Additionally, relapse occurred in 100% of
patients with macrolide resistant strains. These sputum
conversion rates are somewhat surprising given the in-vitro
susceptibility pattern of M. abscessus previously reported
(with 0% isolates susceptible in vitro to fluoroquinolones,
and less than 5% isolates susceptible in vitro to doxycycline)
and the relatively short period of parenteral therapy. These
results, once again, challenge conventional assumptions
about the utility of in-vitro susceptibility testing in the
therapy of NTM disease.
These results also highlight the importance of differen-
tiating between M. abscessus isolates with (M. abscessus ssp
abscessus) and without (M. abscessus ssp bolletii aka
Mycobacterium massiliense) an active erm gene. Subse-
quent work has shown that patients with M. abscessus ssp
bolletii (M. massiliense) have a much more favorable
response to macrolide-based therapy, presumably due to an
inactive erm gene, than patients infected with M. abscessus
ssp abscessus [42,43]. In another interesting recent twist it
has also been recently reported that clarithromycin induces
greater erm gene activity than azithromycin and thus
higher macrolide resistance than azithromycin [44]. They
concluded that azithromycin may be more effective against
M. abscessus ssp abscessus than clarithromycin whereas
both macrolides appear to be equally effective against M.
massiliense (M. abscessus ssp bolletii).
For unclear reasons, in the United States as opposed to
Korea, there appears to be more lung disease caused by M.
abscessus ssp abscessus than M. abscessus ssp bolletii (M.
Top ten essentials of NTM lung disease 423massiliense). However, there is a clear treatment advan-
tage with macrolide-based regimens for M. abscessus or-
ganisms without an active erm gene. Even if a laboratory is
unable to identify M. abscessus isolates to the subspecies
level, any laboratory should be capable of determining the
MIC for macrolide for an M. abscessus isolate after incu-
bation of that isolate in the presence of macrolide.
Akin to the approach towards recalcitrant cavitary MAC
lung disease, surgical resection may warrant consideration
in select M. abscessus (especially ssp M. abscessus patients)
with localized or cavitary disease.
Bottom Line: The optimal therapy for M. abscessus ssp
abscessus lung disease remains problematic and usually
requires one or more parenteral agents. M. abscessus
ssp bolletii (M. massiliense) responds in a more predict-
ably favorable manner to macrolide-containing regimens.
Mycobacterial laboratories must provide sufficient in-
formation to the clinician to allow determination of the
erm gene activity of an M. abscessus isolate.
9) What about the management of other NTM respira-
tory pathogens?M. kansasii remains the most easily treatable of the NTM
pulmonary pathogens. As opposed to most other NTM, there
is a good correlation between in-vitro susceptibilities and
in-vivo response for a variety of antimicrobial agents
including rifamycins, macrolides and fluoroquinolones.
A prospective study of 106 patients with Mycobacterium
malmoense lung disease was performed over a 5-year
period by the British Thoracic Society (BTS) [45]. The re-
sults of 2 years of treatment with rifampin plus ethambutol
were equivalent to rifampin, ethambutol plus isoniazid,
although only 53% of patients were alive at 5 years and 44 of
the original 106 patients (42%) were cured of the infection.
In a follow-up study, the BTS randomly assigned 167 pa-
tients with M. malmoense lung disease to clarithromycin,
rifampin, and ethambutol, or ciprofloxacin, rifampin, and
ethambutol. Overall response rates were low, but the group
receiving clarithromycin had slightly better clinical
response and lower mortality [46].
In an uncontrolled retrospective study of 136 patients with
M. xenopi pulmonary infection, the absence of treatmentwas
associated with a poor prognosis; median survival was 10
months in untreated patients compared with 32 months in
treated patients [47]. Combination therapy with a rifamycin-
containing regimen was associated with improved survival.
These outcomes were not adjusted for comorbidities; there-
fore, the difference in survival cannot be definitively attrib-
uted to treatment. In a similar study from the Netherlands,
multiple different treatment regimens were used in 49 pa-
tients with M. xenopi lung disease, but no specific drug
combination showed consistently superior results [48].
Although pulmonary M. szulgai disease is rare, M. szulgai
isolates are usually clinically significant. Disease occurs
most commonly in patients with underlying lung disease. In
a study that included 12 patients treated for M. szulgai
infection, patients responded well to multiple treatment
regimens, usually including rifampin, ethambutol, and
either clarithromycin or ciprofloxacin [16]. Patients with M.
szulgai lung disease appear more likely to respond totherapy than patients with M. malmoense, M. xenopi, or M.
simiae infection.
M. simiae, when isolated in clinical samples, is more
often a contaminant than a true pathogen. When it is a true
pathogen, however, it is extremely difficult to treat
effectively. To date, there are no predictably effective
drug combinations for treating M. simiae [17]. The treat-
ment of RGM pulmonary disease is highly dependent on the
species isolated, the source of the RGM species isolated
and, as noted earlier, the presence of inducible resistance
genes for macrolides.
M. fortuitum is a low-grade pathogen that infrequently
causes progressive pulmonary disease and usually does not
require specific antibiotic therapy [18]. Clinicians should
be very careful when evaluating the clinical significance of
M. fortuitum respiratory isolates. Overall, it is important
to be confident about the diagnosis, base therapy on in-
vitro susceptibility, use at least two non-macrolide
agents with in-vitro activity against the clinical M. fortu-
itum isolate, treat for at least 12 months of negative
sputum cultures while on therapy (as is recommended for
other nontuberculous respiratory isolates) and avoid mac-
rolides if possible (especially for empiric therapy). Evalu-
ation and treatment of esophageal disease when present is
warranted in those with M. fortuitum lung disease given
the known close association.
Bottom Line: Multi-drug macrolide-containing regi-
mens remain the cornerstone of therapy for most slowly
growing nontuberculous mycobacterial pathogens.
Effective therapy for M. abscessus, the most important
rapidly growing nontuberculous mycobacterial pathogen,
remains elusive. Better therapeutic approaches are ur-
gently needed for almost all NTM respiratory pathogens.
10) Is there a role for the use of macrolide monotherapy
for non-cystic fibrosis bronchiectasis?
Recent data have been published regarding the benefits
of the use of macrolide monotherapy to decrease rates of
exacerbations in patients with COPD and non-cystic fibrosis-
related bronchiectasis [49,50]. Increasing interest and
ongoing multicenter studies are hoping to answer whether
there may be a role for macrolide monotherapy to improve
the natural course of adult non-CF bronchiectasis patients.
The relative tolerance and potential benefit raises complex
questions grounded in the relationship between bronchi-
ectasis and NTM lung disease as well as the deleterious risk
of creating macrolide-resistant NTM lung disease as dis-
cussed above. Without clear data or recommendations
available to direct the clinician, a common approach to the
adult non-CF bronchiectasis patient is similar to the CF
patient and macrolide monotherapy. Specifically, prior to
consideration of the start of macrolide monotherapy NTM
lung disease should be excluded on clinical, radiographic,
and as appropriate, microbiological criteria. Caution should
be exercised before starting macrolide monotherapy in
those adult non-CF bronchiectasis patients with past history
of NTM lung disease given the real possibility of subsequent
relapse or reinfection with the same or different NTM or-
ganism and risk of creating macrolide resistant NTM lung
disease. The use of macrolide monotherapy in those with
established macrolide resistant NTM lung disease for
424 T.R. Aksamit et al.immunomodulatory purposes is also undefined but at least
superficially appears to be justifiable.
Bottom Line: Use of macrolide monotherapy in adult
non-CF bronchiectasis should be cautiously approached
given lack of data thus far from ongoing studies. If
considered, NTM lung disease should be excluded prior to
the start of macrolide monotherapy to avoid creating
macrolide resistant lung disease, especially macrolide
resistant MAC lung disease. Likewise, caution should be
exercised in those with a history of past NTM lung disease.Summary
Nontuberculous mycobacterial lung diseases are encoun-
tered with increasing frequency by clinicians in the U.S.
where the prevalence of NTM lung disease appears to
exceed that of tuberculosis, and at this point represents an
important public-health threat. The recognition and diag-
nosis of NTM lung diseases seems to be improved, perhaps
as a result of increased familiarity, but reliable and effec-
tive treatment of NTM, especially MAC, remains problem-
atic. It is still frustrating that NTM generally do not respond
to antimicrobials based on in-vitro susceptibility testing.
Recent insights into molecular mechanisms of in-vivo drug
resistance in RGM may provide clues to this poorly under-
stood and vexing process.Conflict of interest
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